Patrik Andersson

Patrik Andersson has a strong background in scientific research and has held various roles in the biotech and medical industries. Starting in 2012, they worked as a PhD student at Karolinska institutet, studying tumor biology and the mechanisms of tumor microenvironment in promoting metastasis. Patrik continued their research as a Postdoctoral Researcher at Karolinska institutet until 2017, focusing on tumor biology, vascular biology, and molecular biology.

From 2017 to 2022, Andersson worked as a Postdoctoral Fellow at Harvard Medical School - Massachusetts General Hospital. During this time, they worked on projects involving tumor cell targeting therapy and immunotherapies, with a particular focus on the tumor microenvironment. Patrik designed and executed assays related to tumor cells, myeloid cells, and lymphocytes, and their projects included primary tumors, brain metastatic tumors, and lymph node characterization.

In 2022, Andersson joined Sorrento Therapeutics, Inc. as a Senior Scientist. In this role, they were responsible for target identification and validation, as well as developing new biologics and cell therapy drug candidates. Patrik also established and operated molecular biology, cell biology, and confocal imaging cores within the company. Andersson successfully established three new targets for different projects, utilizing approaches including small molecule approaches, antibody-conjugates, and cell therapies.

Currently, Andersson is working as a Scientist II at Velia.

Patrik Andersson has a Bachelor's degree in Biomedical Sciences from Karolinska Institutet, which they earned between 2007 and 2010. From 2010 to 2011, they worked as a Research Fellow at Karolinska Institutet, focusing on Experimental Oncology. Additionally, during the year 2010, they completed a Practical Course in Molecular Immunology at the same institution. In 2011, they pursued another Research Fellow position at Karolinska Institutet, specializing in Tumor Vascular Biology. Later, in 2014, they attended the General Course in Tumor Biology at Harvard Medical School - Massachusetts General Hospital.